Merck completes $2.7B ArQule acquisition.


Byline: Anthony Vecchione

Kenilworth-based Merck announced on Thursday the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of ArQule Inc. at a purchase price of $20.00 per share.

Merck announced its intention to acquire ArQule in December 2019.

ArQule is a biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. ArQule's lead investigational candidate, ARQ 531, is a novel, oral Bruton's tyrosine kinase (BTK) inhibitor currently in a Phase 2 dose-expansion study for the treatment of B-cell malignancies.

Following the completion of the tender offer, Merck completed the acquisition of ArQule through a merger of...

To continue reading